BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cambrex Corporation (CBM) Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012


11/1/2012 9:32:20 AM

EAST RUTHERFORD, N.J., Oct. 31, 2012 /PRNewswire/ -- Due to complications from the storm affecting the East Coast, Cambrex Corporation (NYSE: CBM, "Cambrex") will now report its results of the third quarter ended September 30, 2012 after the market closes Monday, November 5, 2012

The Company will also host a conference call to discuss the financial results Monday, November 5, 2012 at 4:45 p.m. EST.


Third Quarter 2012 Earnings Conference Call



When:

Monday, November 5, 2012 at 4:45 p.m. Eastern Time



Dial-in:

1-888-430-8705 for U.S.


1-719-325-2455 for International


Passcode: 1704787



Dial-in Replay:

1-888-203-1112 for U.S.


1-719-457-0820 for International


Passcode: 1704787


Available through Monday, November 12, 2012



Webcast:

www.cambrex.com

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.

SOURCE Cambrex Corporation


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->